STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis
Abstract Axitinib resistance remains a serious challenge in the treatment of advanced renal cell carcinoma (RCC), and the underlying mechanisms are not fully understood. Here, we constructed an in vivo axitinib-resistant RCC model and identified the long non-coding RNA STX17-DT as a driver of therap...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-02-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-025-07456-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850190376230453248 |
|---|---|
| author | Yihui Pan Shuang Liu Guannan Shu Minyu Chen Liangmin Fu Cheng Chen Yimeng Chen Qianfeng Zhuang Dong Xue Xiaozhou He |
| author_facet | Yihui Pan Shuang Liu Guannan Shu Minyu Chen Liangmin Fu Cheng Chen Yimeng Chen Qianfeng Zhuang Dong Xue Xiaozhou He |
| author_sort | Yihui Pan |
| collection | DOAJ |
| description | Abstract Axitinib resistance remains a serious challenge in the treatment of advanced renal cell carcinoma (RCC), and the underlying mechanisms are not fully understood. Here, we constructed an in vivo axitinib-resistant RCC model and identified the long non-coding RNA STX17-DT as a driver of therapy resistance in RCC. The expression of STX17-DT was significantly elevated in axitinib-resistant RCC cells and correlated with poorer prognosis in RCC patients. Elevated levels of STX17-DT contributed to the development of resistance to axitinib both in vitro and in vivo. Mechanistically, STX17-DT modulated the stability of IFI6 mRNA by recruiting and binding to hnRNPA1, leading to decreased accumulation of mitochondrial reactive oxygen species (ROS) and attenuated ferroptosis. Meanwhile, STX17-DT was packaged into extracellular vesicles through hnRNPA1, thus transmitting axitinib resistance to other cells. Compared with axitinib monotherapy, combined treatment of axitinib and STX17-DT-targeted in vivo siRNA demonstrated enhanced therapeutic efficacy. These findings indicate a novel molecular mechanism of axitinib resistance in RCC and suggest that STX17-DT may serve as a prognostic indicator and potential therapeutic target to overcome resistance to targeted therapy. |
| format | Article |
| id | doaj-art-08d752ba7a974675b42af37286e55b1f |
| institution | OA Journals |
| issn | 2041-4889 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Death and Disease |
| spelling | doaj-art-08d752ba7a974675b42af37286e55b1f2025-08-20T02:15:19ZengNature Publishing GroupCell Death and Disease2041-48892025-02-0116111410.1038/s41419-025-07456-9STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosisYihui Pan0Shuang Liu1Guannan Shu2Minyu Chen3Liangmin Fu4Cheng Chen5Yimeng Chen6Qianfeng Zhuang7Dong Xue8Xiaozhou He9Department of Urology, the Third Affiliated Hospital of Soochow UniversityDepartment of Oncology, the Third Affiliated Hospital of Soochow UniversityDepartment of Urology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Medical UniversityDepartment of Urology, the First Affiliated Hospital, Sun Yat-sen UniversityDepartment of Urology, the Second Xiangya Hospital, Central South UniversityDepartment of Urology, the Third Affiliated Hospital of Soochow UniversityDepartment of Urology, the Third Affiliated Hospital of Soochow UniversityDepartment of Urology, the Third Affiliated Hospital of Soochow UniversityDepartment of Urology, the Third Affiliated Hospital of Soochow UniversityDepartment of Urology, the Third Affiliated Hospital of Soochow UniversityAbstract Axitinib resistance remains a serious challenge in the treatment of advanced renal cell carcinoma (RCC), and the underlying mechanisms are not fully understood. Here, we constructed an in vivo axitinib-resistant RCC model and identified the long non-coding RNA STX17-DT as a driver of therapy resistance in RCC. The expression of STX17-DT was significantly elevated in axitinib-resistant RCC cells and correlated with poorer prognosis in RCC patients. Elevated levels of STX17-DT contributed to the development of resistance to axitinib both in vitro and in vivo. Mechanistically, STX17-DT modulated the stability of IFI6 mRNA by recruiting and binding to hnRNPA1, leading to decreased accumulation of mitochondrial reactive oxygen species (ROS) and attenuated ferroptosis. Meanwhile, STX17-DT was packaged into extracellular vesicles through hnRNPA1, thus transmitting axitinib resistance to other cells. Compared with axitinib monotherapy, combined treatment of axitinib and STX17-DT-targeted in vivo siRNA demonstrated enhanced therapeutic efficacy. These findings indicate a novel molecular mechanism of axitinib resistance in RCC and suggest that STX17-DT may serve as a prognostic indicator and potential therapeutic target to overcome resistance to targeted therapy.https://doi.org/10.1038/s41419-025-07456-9 |
| spellingShingle | Yihui Pan Shuang Liu Guannan Shu Minyu Chen Liangmin Fu Cheng Chen Yimeng Chen Qianfeng Zhuang Dong Xue Xiaozhou He STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis Cell Death and Disease |
| title | STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis |
| title_full | STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis |
| title_fullStr | STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis |
| title_full_unstemmed | STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis |
| title_short | STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis |
| title_sort | stx17 dt facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ros accumulation and ferroptosis |
| url | https://doi.org/10.1038/s41419-025-07456-9 |
| work_keys_str_mv | AT yihuipan stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT shuangliu stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT guannanshu stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT minyuchen stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT liangminfu stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT chengchen stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT yimengchen stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT qianfengzhuang stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT dongxue stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis AT xiaozhouhe stx17dtfacilitatesaxitinibresistanceinrenalcellcarcinomabyinhibitingmitochondrialrosaccumulationandferroptosis |